Shanghai Pharmaceuticals Holding Co Class H ((SHPMF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Pharmaceuticals Holding Co. is conducting a Phase I clinical study titled ‘A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors.’ The study aims to assess the safety and tolerability of SPH5030 tablets in patients with HER2-positive advanced solid tumors, a significant area of research given the aggressive nature of these cancers.
The intervention being tested is the SPH5030 tablet, an experimental drug administered orally to patients. The purpose of this drug is to treat HER2-positive advanced solid tumors, with patients receiving varying doses to determine optimal safety and effectiveness.
This interventional study follows a single-group assignment model without masking, focusing primarily on treatment. Participants are allocated to receive one of five different doses of SPH5030 tablets, taken once or twice daily.
The study began on February 8, 2022, with primary completion expected soon, and the last update was submitted on August 15, 2025. These dates are crucial as they indicate the study’s progress and potential upcoming results.
The market implications of this study are significant for Shanghai Pharmaceuticals, as positive results could enhance their stock performance and investor confidence. Given the competitive landscape of cancer treatments, successful outcomes could position the company favorably against competitors.
The study is currently recruiting, with further details available on the ClinicalTrials portal.